Latest:
Global Updates in Advanced Gastric Cancer from ESMO 2020
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Johanna C. Bendell, MD
Latest:
Dr. Bendell on the Next Steps Following Progression on Immunotherapy in MSI-H CRC
Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the next steps following progression on checkpoint inhibitors in microsatellite instability-high (MSI-H) colorectal cancer (CRC).
John A. D'Orazio, MD, PhD
Latest:
Dr. D'Orazio on UV Signature Mutations in Melanoma
John A. D'Orazio, MD, PhD, associate professor, Department of Pediatrics, College of Medicine, University of Kentucky Markey Cancer Center, discusses ongoing research exploring ultraviolet radiation signature mutations in patients with melanoma.
John A. Glaspy, MD
Latest:
Dr. Glaspy on Immunotherapy in Endometrial Cancer
John A. Glaspy, MD, professor of medicine, Jonsson Comprehensive Cancer Center (JCCC), director, JCCC Clinical Research Unit and Women's Cancer Research Program, University of California, Los Angeles School of Medicine, discusses immunogenicity in endometrial cancer.
John A. Kosteva, MD
Latest:
Dr. Kosteva on Single-Agent Versus Combination Immunotherapy in NSCLC
John A. Kosteva, MD, clinical assistant professor of medicine, University of Pennsylvania School of Medicine, Abramson Cancer Center, discusses the adoption of immunotherapy into the treatment paradigm for patients with non–small cell lung cancer (NSCLC).
John A. Martignetti, MD, PhD
Latest:
Dr. Martignetti on Next-Generation Sequencing in Fallopian Tube Cancer
John A. Martignetti, MD, PhD, associate professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, network director for the Laboratory for Translational Research at the Western Connecticut Health Network, discusses next-generation sequencing for patients with fallopian tube cancer.
John C. Araujo, MD, PhD
Latest:
Dr. Araujo on Emerging Data on Radium-223 for Patients With mCRPC
John C. Araujo, MD, PhD, assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses emerging data with radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Araujo shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.